Biotech News

Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates

Genelux (GNLX)GeneluxEarnings

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --

-- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer --

Related news

Genelux

Oncolytic Immunotherapy Genelux develops replication-competent oncolytic viruses designed to destroy tumor cells and stimulate systemic antitumor immunity. Its platform is being studied through regional and systemic administration approaches. Olvi-Vec Olvi-Vec is the company's lead vaccinia-virus candidate. The registrational...

Recent company news

Stock data

Close
2.28 USD
Market cap
132.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States